For instance, zenocutuzumab, a bsAb against HER2 and HER3, potently inhibits heregulin (HRG)-driven signaling of HER2-HER3 heterodimerization and has received accelerated FDA approval for patients with NRG1 fusion-positive non-small cell lung cancer (NSCLC) or pancreatic adenocarcinoma (18). This evidence concerns the gene ERBB3 and non-small cell lung carcinoma.